Grifols in a massive sell-off - looking for opportunities
The chart is self-explanatory!
Price to earnings getting very low, company is solid and should see a bounce sooner or later at major support levels.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.230EUR
59.32 MEUR
6.59 BEUR
256.87 M
About GRIFOLS S.A.
Sector
CEO
Nacho Abia
Headquarters
Barcelona
Website
Employees (FY)
23.74 K
Founded
1940
ISIN
ES0171996095
FIGI
BBG007Z171K1
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Buy $GRFS - NRPicks 22 AprGrifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
Buy $GRFS - NRPicks 11 MarGrifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA mar
Predicción GRF 28-12-2021Predicción para GRF en Corto. Recomendada por nuestro algoritmo de IA. El horizonte temporal de la recomendación es 5 días.
Are we at the bottom yet?Grifols stock has been heavely punished during 2021.
First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra
GRF is set for actionA nice triangle at the end of a long way down. Even though we did not face the ultimate action, the chances are the stage is set for upside. The best case is to see the short-lived break down but the solo break up is valid as well.
GRIFOLS: Throw-back becoming a reality?After surpassing Fib 0.5, it looks like the stock is heading towards 0.382 level (21.81). Right now the company is immersed in a share repurchase program since 12/03/2021 and it has already acquired 19.23% of its €125 million valued shares objective. Maybe the company's financial advisers are playin
GRIFOLS: Results day coming on Feb 26. Then to the moon?68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (speciall
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0RDV is 6.590 EUR — it has increased by 1.50% in the past 24 hours. Watch GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS stocks are traded under the ticker 0RDV.
0RDV stock has risen by 1.82% compared to the previous week, the month change is a 9.83% rise, over the last year GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS has showed a 16.05% decrease.
We've gathered analysts' opinions on GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS future price: according to them, 0RDV price has a max estimate of 14.85 EUR and a min estimate of 6.30 EUR. Watch 0RDV chart and read a more detailed GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS stock forecast: see what analysts think of GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS and suggest that you do with its stocks.
0RDV reached its all-time high on Feb 21, 2020 with the price of 23.400 EUR, and its all-time low was 4.915 EUR and was reached on Mar 6, 2024. View more price dynamics on 0RDV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0RDV stock is 1.73% volatile and has beta coefficient of 1.19. Track GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS stock price on the chart and check out the list of the most volatile stocks — is GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS there?
Today GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS has the market capitalization of 4.50 B, it has decreased by 1.38% over the last week.
Yes, you can track GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS financials in yearly and quarterly reports right on TradingView.
GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS is going to release the next earnings report on Jul 25, 2024. Keep track of upcoming events with our Earnings Calendar.
0RDV earnings for the last quarter are 0.08 EUR per share, whereas the estimation was 0.10 EUR resulting in a −19.01% surprise. The estimated earnings for the next quarter are 0.21 EUR per share. See more details about GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS earnings.
GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS revenue for the last quarter amounts to 1.63 B EUR despite the estimated figure of 1.63 B EUR. In the next quarter revenue is expected to reach 1.82 B EUR.
0RDV net income for the last quarter is 55.99 M EUR, while the quarter before that showed 59.54 M EUR of net income which accounts for −5.96% change. Track more GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS financial stats to get the full picture.
GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS dividend yield was 0% in 2023, and payout ratio reached 0%. The year before the numbers were 0% and 0% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 1, 2024, the company has 23.74 K employees. See our rating of the largest employees — is GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS EBITDA is 1.30 B EUR, and current EBITDA margin is 17.90%. See more stats in GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS financial statements.
Like other stocks, 0RDV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS stock shows the sell signal. See more of GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.